Development

Kainova Therapeutics' DT-9081 shows early promise in Phase I advanced solid tumors trial

Montreal-based Kainova Therapeutics announced topline results from its Phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, in patients with...

Kainova Therapeutics Reports Phase I Data for Oral EP4 Receptor Antagonist DT-9081 in Advanced Solid Tumors

Montreal-based Kainova Therapeutics announced topline results from its Phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, in patients with advanced, recurrent, and metastatic solid tumors. The data, which showed no dose-limiting toxicities and early signs of anti-tumor activity, mark the first clinical validation of selective EP4 antagonism in oncology patients and position Kainova to advance DT-9081 into combination studies with immune checkpoint inhibitors.

Trial specifics

The Phase I EPRAD study was an open-label, dose-escalation trial conducted across four sites in France and Belgium. It enrolled adults with advanced, recurrent, or metastatic solid tumors. The study evaluated DT-9081 at multiple oral dose levels, though specific doses and patient numbers were not disclosed in the topline readout. Primary objectives centered on safety, tolerability, pharmacokinetics, and pharmacodynamics. The company reported that all primary objectives were met: no dose-limiting toxicities occurred at any dose level, exposure was dose-proportional, and sustained EP4 receptor engagement was observed across all cohorts. Early signs of anti-tumor activity were noted, though no quantitative efficacy data were provided. The study has been completed, and no extension phase was described.

Kainova's Chief Medical Officer Jean-Marie Cuillerot said the study "generated a clear and coherent dataset that precisely characterizes DT-9081's clinical profile." CEO Sean MacDonald stated the findings "reinforce the relevance of GPCR-modulating strategies in addressing complex immune pathways." The company has not disclosed specific regulatory timelines for advancing DT-9081 into later-stage trials, though the press release positions the molecule as a candidate for combination with immune checkpoint inhibitors. DT-9081 has no prior regulatory approvals in any indication.

Research context

DT-9081 blocks the EP4 receptor, one of four receptors for prostaglandin E2 (PGE2). In the tumor microenvironment, COX-2-positive cancer cells produce PGE2, which signals through EP4 to suppress CD8+ T cell function, expand regulatory T cells, and promote immunosuppressive myeloid cell populations. By selectively antagonizing EP4, DT-9081 aims to reverse this PGE2-driven immune evasion and restore anti-tumor immunity. The approach differs from broad COX inhibition — which carries gastrointestinal and cardiovascular risks — by targeting a single downstream receptor. Principal investigator Jean-Pascal Machiels noted that because chemotherapy itself can trigger PGE2 production, EP4 inhibition offers "a rational and versatile strategy to overcome resistance."

The AllSci BriefSystematic R&D and deal news. Daily.

The EP4 receptor antagonist class in oncology remains early-stage, and no approved therapies target this mechanism. Preclinical work with DT-9081 has shown activity in models of triple-negative breast cancer, sarcoma, and colorectal cancer, both alone and combined with chemotherapy or checkpoint inhibitors. The competitive landscape for DT-9081 is defined less by direct EP4 competitors than by the broader field of agents designed to overcome checkpoint inhibitor resistance in advanced solid tumors. Key programs include:

  • Pembrolizumab (Merck) and nivolumab (Bristol Myers Squibb), anti-PD-1 antibodies in Phase III across multiple solid tumor settings, represent the standard-of-care immunotherapies that DT-9081 would aim to complement rather than replace.
  • Tiragolumab (Roche) and domvanalimab (Arcus Biosciences/Gilead), anti-TIGIT antibodies in Phase II combination studies, target a different checkpoint axis but share the strategic goal of deepening responses to PD-1/PD-L1 blockade.

No other selective oral EP4 antagonist oncology program with disclosed clinical data was identified in the source material, suggesting Kainova occupies a relatively uncrowded mechanistic niche. The company also lists a Treg-depleting anti-CCR8 antibody and a pre-IND PAR2 biased antagonist in its pipeline, though no clinical data have been reported for either. Whether DT-9081's early activity signals translate into measurable tumor responses in combination regimens will determine the molecule's path forward.


Spot something wrong? Report an issue with this article